Vimarsana
Biggest News Aggregation in the World

Page 17 - Looking Statement News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Looking Statement. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Looking Statement Today - Breaking & Trending Today

Merck's KEYTRUDA® (pembrolizumab) Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With Renal Cell Carcinoma (RCC) at an Increased Risk of Recurrence Following Nephrectomy -January 27, 2024 at 10:01 am EST - Vimarsana News

Merck's KEYTRUDA® (pembrolizumab) Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With Renal Cell Carcinoma (RCC) at an Increased Risk of Recurrence Following Nephrectomy -January 27, 2024 at 10:01 am EST

Published: January 27, 2024

KEYNOTE-564 is the first Phase 3 trial to demonstrate superior overall survival with adjuvant therapy compared to placebo in patients with RCC Late-breaking OS results selected for the official...

Source: marketscreener.com
Related Topics:
United StatesTonik ChoueiriNancy KohlbergHarvard Medical SchoolExchange CommissionAsco Gu Press ProgramDana Farber Cancer InstituteLank CenterAmerican Society Of Clinical OncologyStatement Of Merck Co IncMerck Research LaboratoriesEuropean UnionAkeso IncMerck Co IncClinical OncologyCancers SymposiumGenitourinary OncologyHarvard MedicalMarjorie GreenMerck ResearchPositive ScoreSelected Important SafetyImportant Safety InformationFatal Immune Mediated AdverseWhich Can Present With Diabetic
Merck's KEYTRUDA® (pembrolizumab) Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With Renal Cell Carcinoma (RCC) at an Increased Risk of Recurrence Following Nephrectomy | Region - Vimarsana News

Merck's KEYTRUDA® (pembrolizumab) Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With Renal Cell Carcinoma (RCC) at an Increased Risk of Recurrence Following Nephrectomy | Region

Published: January 27, 2024

RAHWAY, N.J.--(BUSINESS WIRE)--Jan 27, 2024--

Source: eagletribune.com
Related Topics:
United StatesMichael McardlePeter DannenbaumDamini ChokshiNancy KohlbergTonik ChoueiriJulie CunninghamAkeso IncDana Farber Cancer InstituteStatement Of Merck Co IncEuropean UnionAsco Gu Press ProgramMerck Co IncMerck Research LaboratoriesExchange CommissionLank CenterHarvard Medical SchoolAmerican Society Of Clinical OncologyClinical OncologyCancers SymposiumGenitourinary OncologyHarvard MedicalMarjorie GreenMerck ResearchPositive Score
Merck's KEYTRUDA® (pembrolizumab) Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With Renal Cell Carcinoma (RCC) at an Increased Risk of Recurrence Following Nephrectomy | Business - Vimarsana News

Merck's KEYTRUDA® (pembrolizumab) Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With Renal Cell Carcinoma (RCC) at an Increased Risk of Recurrence Following Nephrectomy | Business

Published: January 27, 2024

RAHWAY, N.J.--(BUSINESS WIRE)--Jan 27, 2024--

Source: valdostadailytimes.com
Related Topics:
United StatesPeter DannenbaumDamini ChokshiTonik ChoueiriMichael McardleNancy KohlbergJulie CunninghamMerck Research LaboratoriesExchange CommissionHarvard Medical SchoolLank CenterAmerican Society Of Clinical OncologyDana Farber Cancer InstituteEuropean UnionAkeso IncStatement Of Merck Co IncAsco Gu Press ProgramMerck Co IncClinical OncologyCancers SymposiumGenitourinary OncologyHarvard MedicalMarjorie GreenMerck ResearchPositive Score
Merck's KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) as Adjuvant Therapy Versus Observation in High-Risk Patients With Localized Muscle-Invasive and Locally Advanced Urothelial Carcinoma After Surgery -January 26, 2024 at 10:01 am EST - Vimarsana News

Merck's KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) as Adjuvant Therapy Versus Observation in High-Risk Patients With Localized Muscle-Invasive and Locally Advanced Urothelial Carcinoma After Surgery -January 26, 2024 at 10:01 am EST

Published: January 26, 2024

KEYTRUDA doubled median DFS as adjuvant therapy versus observation – 29 months versus 14 months – in these patients AMBASSADOR /KEYNOTE-123 is the first positive trial for KEYTRUDA as adjuvant...

Source: marketscreener.com
Related Topics:
United StatesMerck Co IncAlliance For Clinical Trials In OncologyDevelopment AgreementStatement Of Merck Co IncMerck Research LaboratoriesNational Cancer InstituteExchange CommissionNational Clinical Trials Network GroupsGenitourinary Malignancies BranchNational Institutes Of HealthAmerican Society Of Clinical OncologyClinical OncologyCancers SymposiumAndrea ApoloBladder Cancer SectionNational InstitutesMarjorie GreenMerck ResearchClinical TrialsNational Clinical Trials NetworkCooperative ResearchBacillus Calmette GuerinSelected Important SafetyImportant Safety Information
Blueharbor bank Reports Fourth Quarter 2023 Net Income - Vimarsana News

Blueharbor bank Reports Fourth Quarter 2023 Net Income

Published: January 26, 2024

MOORESVILLE, N.C., Jan. 26, 2024 /PRNewswire/ -- blueharbor bank today reported net income of $1,510,772 and $0.50 per diluted share for the fourth quarter of 2023, a decrease of 26% or $535,250...

Source: marketscreener.com
Related Topics:
Iredell CountyNorth CarolinaUnited StatesJim MarshallCurrent Expected Credit LossChief Executive OfficerMarket PresidentSelected Financial Data ScheduleLooking StatementSheet DataPer Share DataInterest IncomePerformance RatiosTotal AssetsEquity TierBased Capital